Absorption of a novel prodrug of L-dopa, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355). In vitro and in situ studies

Drug Metab Dispos. 1990 Sep-Oct;18(5):621-5.

Abstract

Absorption mechanism and absorption site of a prodrug of L-DOPA, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355, 1) was investigated using rats. Prodrug 1 (0.5 mM) was taken up by intestinal tissue segments time-dependently in vitro at pH 6.0. However, the rate of uptake was less than that of L-dopa. Inhibitors of the amino acid active transport system (L-Phe, dinitrophenol, ouabain) had no effect on the uptake of prodrug 1. In the intestinal tissue segments, prodrug 1 was extensively hydrolyzed by diisopropylfluorophosphate-sensitive esterase(s). To characterize the absorption site, gastrointestinal tracts were ligated to make acute loops in situ and prodrug 1 or L-dopa was injected into the loops. L-dopa disappeared rapidly from the lumen of the jejunum. In contrast, prodrug 1 disappeared rapidly from the ileum rather than the duodenum or jejunum. From these results, it was suggested that prodrug 1 was slowly absorbed primarily from the lower small intestine.

MeSH terms

  • Animals
  • Dinitrophenols / pharmacology
  • In Vitro Techniques
  • Intestinal Absorption
  • Isoflurophate / pharmacology
  • Levodopa / analogs & derivatives*
  • Levodopa / pharmacokinetics*
  • Male
  • Ouabain / pharmacology
  • Phenylalanine / pharmacology
  • Prodrugs / pharmacokinetics*
  • Rats

Substances

  • Dinitrophenols
  • Prodrugs
  • L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine
  • Isoflurophate
  • Levodopa
  • Phenylalanine
  • Ouabain